Table 1.
Patient Demographics of Patients Included From the TOPPIC Trial, With and Without Clinical Recurrencea
| Clinical recurrence (n = 40) | No recurrence (n = 189) | P value | |
|---|---|---|---|
| Female, n (%) | 26 (65.0) | 115 (60.8) | .9 |
| Age, y, median (IQR) | 32.2 (27.8–41.0) | 40.0 (29.0–49.8) | .02 |
| Baseline CDAI (IQR) | 124.5 (73.7–223.0) | 112.0 (64.5–164.0) | .2 |
| Disease location, n (%) | 0.7 | ||
| L1 ileal | 14 (35.0) | 74 (39.2) | |
| L3 ileocolonic | 26 (65.0) | 115 (60.8) | |
| Disease behavior, n (%) | 0.8 | ||
| Inflammatory B1 | 17 (42.5) | 73 (38.9) | |
| Stricturing B2 | 17 (42.5) | 89 (47.3) | |
| Penetrating B3 | 6 (15.0) | 26 (13.8) | |
| Previous infliximab, n (%) | 7 (17.5) | 29 (15.7) (3missing) | 1 |
| Previous azathioprine, n (%) | 22 (55) | 102 (54.3) | 1 |
| Previous surgery, n (%) | 9 (22.5) | 62 (32.8) | .3 |
| Current smoker, n (%) | 14 (35) | 40 (21.2) | .1 |
| Biochemistry median (IQR) | |||
| CRP, mg/L | 3.7 (3–6) | 4 (3–7) | .7 |
| ESR | 13 (6–22) (3 missing) | 12 (5–19) (50 missing) | .4 |
| Albumin | 42 (41–46) | 43 (40–45) | .8 |
| White cell count | 7.1 (5.5–8.5) | 6.6 (5.5–8.1) | .4 |
NOTE. Results are presented as median, interquartile range. Nonparametric statistics are used to compare groups, chi-square for categorical data and Wilcox rank sum test for continuous data.
CDAI, Crohn’s disease activity index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range;
a
Defined as increase in CDAI of more than 150 and an increase of 100 points from baseline measurement and institution of immunosuppressive treatment or further surgery.